Skip to main content
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

RAPT Therapeutics, Inc. - Common Stock (NQ:RAPT)

17.82 +0.40 (+2.30%)
Streaming Delayed Price Updated: 2:07 PM EDT, Sep 16, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about RAPT Therapeutics, Inc. - Common Stock

< Previous 1 2 3 4 Next >
There are notable gap-ups and gap-downs in today's session.
Let's have a look at what is happening on the US markets on Tuesday. Below you can find the gap up and gap down stocks in today's session. 
Via Chartmill
Rapt Therapeutics Get A Bullish Recommendation On ‘Significant Opportunity’ For Allergy Drug Candidate: Retail Worries About Cash Position
Clear Street’s initiated with a $3 price target, highlighting RPT904b as a “potentially best-in-class anti-IgE antibody.” 
Via Stocktwits
Topics ETFs
12 Health Care Stocks Moving In Thursday's After-Market Session
 
Via Benzinga
12 Health Care Stocks Moving In Tuesday's Intraday Session
 
Via Benzinga
RAPT Therapeutics: Q4 Earnings Insights
 
Via Benzinga
12 Health Care Stocks Moving In Friday's Intraday Session
 
Via Benzinga
12 Health Care Stocks Moving In Friday's After-Market Session
 
Via Benzinga
Futures Slide As Bond Yields Jump To 6 Month High
US stock futures and Treasuries dropped as muted trading resumed after the Christmas holiday, with investors looking to initial jobless claims data and a government bond auction later on Thursday. 
Via Talk Markets
Topics Bonds Commodities Cryptocurrencies
12 Health Care Stocks Moving In Thursday's Pre-Market Session
 
Via Benzinga
This Progressive Analyst Turns Bullish; Here Are Top 3 Upgrades For Thursday
 
Via Benzinga
12 Health Care Stocks Moving In Monday's Pre-Market Session
 
Via Benzinga
Why RAPT Therapeutics Stock Gained Over 100% On Monday?
RAPT Therapeutics partners with Shanghai Jemincare to develop RPT904, a potential alternative to Xolair, for food allergies. $35M upfront payment. 
Via Benzinga
US Stocks Mixed, Dow Tumbles 150 Points
 
Via Benzinga
Topics Stocks
12 Health Care Stocks Moving In Monday's Pre-Market Session
 
Via Benzinga
Crude Oil Down 3%; Aramark Posts Upbeat Earnings
 
Via Benzinga
Nasdaq Moves Lower; Canaan Shares Surge
 
Via Benzinga
Rapt Therapeutics Stock Plummets, Terminates Asthma Trial Due To Patient's Liver Injury
RAPT Therapeutics stock falls after halting its zelnecirnon program following FDA clinical hold. Company shifts focus. 
Via Benzinga
Dow Jumps Over 400 Points; Monday.com Shares Fall After Q3 Results
 
Via Benzinga
Topics Stocks
12 Health Care Stocks Moving In Wednesday's Intraday Session
 
Via Benzinga
10 Health Care Stocks Moving In Monday's Pre-Market Session
 
Via Benzinga
12 Health Care Stocks Moving In Wednesday's Intraday Session
 
Via Benzinga
RAPT Stock Earnings: RAPT Therapeutics Beats EPS for Q2 2024
RAPT stock results show that RAPT Therapeutics beat analyst estimates for earnings per share the second quarter of 2024. 
Via InvestorPlace
12 Health Care Stocks Moving In Monday's After-Market Session
 
Via Benzinga
Top 5 Health Care Stocks Which Could Rescue Your Portfolio This Month
 
Via Benzinga
What's Going On With Dermatitis-Focused RAPT Therapeutics Stock On Thursday?
RAPT Therapeutics closes Phase 2 trials for zelnecirnon in atopic dermatitis & asthma following FDA clinical hold due to liver failure. 
Via Benzinga
Why Duolingo Shares Are Trading Lower By Around 18%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
 
Via Benzinga
RAPT Stock Earnings: RAPT Therapeutics Beats EPS for Q1 2024
RAPT stock results show that RAPT Therapeutics beat analyst estimates for earnings per share the first quarter of 2024. 
Via InvestorPlace
12 Health Care Stocks Moving In Thursday's Intraday Session
 
Via Benzinga
3 Biotech Stocks to Dump Before They Go to Zero
These biotech stocks to sell are burning through cash at an alarming rate and seem destined for zero, making them prime targets for selling. 
Via InvestorPlace
RAPT Stock Earnings: RAPT Therapeutics Beats EPS for Q4 2023
RAPT stock results show that RAPT Therapeutics beat analyst estimates for earnings per share the fourth quarter of 2023. 
Via InvestorPlace
< Previous 1 2 3 4 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.